JPRN-jRCTs061210002招募中3 期
A multicenter, open-label, single-blind, randomized, parallel-group study to evaluate the utility of indigocarmine and acetic acid-indigocarmine mixture (AIM) for the diagnosis of colonic serrated lesions in the right side colon - A multicenter, open-label, single-blind, randomized, parallel-group study to evaluate the utility of indigocarmine and acetic acid-indigocarmine mixture (AIM) for the diagnosis of colonic serrated lesions in the right side colon (cAIM study)
Kinugasa Hideaki0 个研究点目标入组 1,311 人开始时间: 2021年4月16日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1,311
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 90age old（—）
- 性别
- All
入选标准
- •(1) Patients who are between 20 years and 90 years old at the time of obtaining consent
- •(2) A person for whom the patient's written consent has been obtained
- •(3) Patients who are scheduled for screening colonoscopy (e.g., fecal occult blood, cancer screening, and colonoscopy with no endoscopic treatment within 1 year)
排除标准
- •(1) Familial colorectal adenomatosis, Lynch syndrome, serrated polyp syndrome(SPS)
- •(2) Patients with a history of colorectal cancer surgery
- •(3) Patients with endoscopic treatment of the colon within 1 year
- •(4) Ulcerative colitis and Crohn's disease
- •(5) Difficulty with endoscopic examination and treatment due to inability to temporarily stop taking antithrombotic or anticoagulant drugs
- •(6) Patents with an infectious disease that requires systemic treatment
- •(7) Pregnant and lactating women
- •(8) Patients with a history of hypersensitivity to indigocarmine or acetic acid
- •(9) Patients who are deemed unsuitable as research subjects by the principal investigator or sub-researcher
研究者
相似试验
尚未招募
不适用
The usefulness of AIM in colonoscopySerrated lesionJPRN-UMIN000043854Okayama University1,311
已完成
不适用
A multi-center, single-dose, open-label, randomized, parallel group study to investigate the reduction of initial taspoglutide Cmax after administration of 20 mg taspoglutide 10% Sustained Release Formulation (SRF) using three modified formulations as compared to the current Phase 3 formulation in healthy volunteers.diabetes mellitus type 210018424diabetesNL-OMON34034Hoffmann-La Roche100
进行中（未招募）
1 期
A study with dose de-escalation of coventional or biologic treatments in early rheeumatoid arthritis in patients with low disease activity.EUCTR2014-002374-36-SEThe Karolinska Institutet, ClinTRID500
进行中（未招募）
1 期
A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.Rheumatoid arthritis (RA)MedDRA version: 19.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-004720-35-DKKarolinska Institutet800
已完成
4 期
A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.arthritis10003816Rheumatoid ArthritisNL-OMON50439Ronald van Vollenhove/Karolinska Instituut (clinTRID)120